Trial Profile
A Randomized, Placebo-controlled, Double-blind Study of LY2216684 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Edivoxetine (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 27 Sep 2016 Results of pooled analysis from 4 adjunctive treatment trials and 1 monotherapy trial (n=2561) published in the Journal of Clinical Psychiatry.
- 01 Mar 2016 Results of pooled analysis of this and other 2 trials (NCT01187407 and NCT01185340) published in the Journal of Clinical Psychiatry
- 05 Dec 2013 Top-line results published in an Eli Lilly media release.